1,649 results on '"Joniau, S"'
Search Results
2. Benefits of early salvage therapy on oncological outcomes in high-risk prostate cancer with persistent PSA after radical prostatectomy
3. Two-year Quality of Life (QoL) outcomes of the randomized phase II trial ARNEO: Neoadjuvant degarelix with or without apalutamide prior to radical prostatectomy for high-risk prostate cancer
4. Natural history of pN1 prostate cancer after radical prostatectomy: Competing risk analysis from a large multi-institutional series
5. Can we use immunohistochemistry as predicting factor of successful treatment with intensified neoadjuvant treatment in high-risk prostate cancer: A subanalysis of the ARNEO trial
6. Correlation between the location of the index tumour and the location of positive lymph nodes in high-risk prostate cancer – a monocentric positive lymph node mapping study
7. Three-year oncological outcomes of the randomized phase II trial ARNEO: Neoadjuvant degarelix with or without apalutamide prior to radical prostatectomy for high-risk prostate cancer
8. The more you see the more you miss. PSMA PET/CT is still affected by a substantial risk of underestimation in prostate cancer patients undergoing radical prostatectomy
9. External validation of the available nomograms for the identification of candidates for a staging extended pelvic lymph node dissection at the time of radical prostatectomy in prostate cancer patients preoperatively staged with PSMA PET
10. Correlation of quality control indicators for transurethral resection of the bladder tumor with oncological outcomes: Results from a Flemish prospective registry
11. Oncologic outcomes of template vs. radio-guided salvage lymph node dissection for node-only recurrent prostate cancer: Results from a multi-institutional collaboration
12. Benchmarking Flemish centers for quality control indicators for transurethral resection of the bladder tumor
13. Enhancing patient selection for salvage radical prostatectomy: A new risk-stratification model from a large retrospective cohort
14. Oncological outcomes of pN1 prostate cancer patients treated with radical prostatectomy: Does molecular imaging have a prognostic impact? Results of a large, multi-institutional series
15. Can we rely on available models predicting pathological outcomes in prostate cancer patients staged with 68-Ga PSMA-PET/CT? External validation of the existing nomograms for extracapsular extension and seminal vesicle invasion at radical prostatectomy and development of a novel tool including intraprostatic SUVmax
16. Risk factors for residual disease at re-TUR in a large cohort of T1G3 patients
17. Salvage Radiotherapy for Prostate Cancer
18. Surgical management of acquired rectourethral fistula: a retrospective analysis of 52 consecutive patients
19. Outcomes of Cytoreductive Radical Prostatectomy for Oligometastatic Prostate Cancer on PSMA-PET: Results of a Multicenter, European Study
20. Progression-Directed Therapy in Oligoprogressive Castration-Refractory Prostate Cancer: Results of the Prospective Single-Arm Phase II MEDCARE Trial
21. Radical prostatectomy after vascular-targeted photodynamic therapy (VTP) with TOOKAD® : feasibility, early and intermediate results
22. Predictors of oncological outcomes in T1G3 patients treated with BCG who undergo radical cystectomy
23. Recurrence, progression and cancer-specific mortality according to stage at re-TUR in T1G3 bladder cancer patients treated with BCG: not as bad as previously thought
24. The survival impact of neoadjuvant hormonal therapy before radical prostatectomy for treatment of high-risk prostate cancer
25. Characterizing prostate cancer risk through multi-ancestry genome-wide discovery of 187 novel risk variants.
26. Progression of high-risk non-muscle invasive bladder cancer correlates with immune phenotypes and Fibroblast Activation Protein-α (FAP)
27. Salvage vesiculectomy for local prostate cancer recurrence: surgical technique, complications and early postoperative outcomes
28. Estimating postoperative renal function after surgery for nonmetastatic renal masses: A systematic review of available prediction models
29. Salvage vesiculectomy for local prostate cancer recurrence: PSA response and oncological outcomes
30. 174TiP SPARKLE: A new spark in treating oligorecurrent prostate cancer: Adding systemic treatment to stereotactic body radiotherapy or metastasectomy: Key to long-lasting event-free survival?
31. Long-Term Outcomes and Genetic Predictors of Response to Metastasis Directed Therapy vs. Observation in Oligometastatic Castration-Sensitive Prostate Cancer: A Pooled Analysis of the STOMP and ORIOLE Trials
32. Who is the right patient for salvage radical prostatectomy? oncological outcomes compared between EAU guidelines-compliant and non-compliant patients
33. Development and validation of a novel nomogram predicting long-term progression in patients treated with early salvage radiation therapy after radical prostatectomy: the key role of PSA kinetics
34. How to optimize patient selection before salvage lymph node dissection for nodal recurrent prostate cancer: a novel risk stratification tool
35. The risk of recurrence in cN1 prostate cancer patients treated with radical prostatectomy varies according to the type preoperative staging. a comparison between 68ga-PSMA-PET versus conventional imaging in a large, multi-institutional study
36. Toxicity profile of immediate post-prostatectomy radiation therapy: results from a large multi-institutional series
37. What is the optimal management of nodal oligorecurrent prostate cancer? results from a large series of patients treated with salvage lymph node dissection
38. Oncological outcomes, patterns of recurrence and impact of competing causes of mortality in clinically node-positive prostate cancer patients treated with radical prostatectomy
39. 1381P A transcriptomic signature of AR activity prognosticates development of castration-resistance following metastasis-directed therapy in oligometastatic castration-sensitive prostate cancer
40. Older patients with low Charlson score and high-risk prostate cancer benefit from radical prostatectomy
41. Radikale Prostatektomie (RP) oder Radiotherapie (RT) beim metastasierten, hormonnaiven Prostatakarzinom (PCA) mit geringer Metastasenlast: Ein indirekter Vergleich mit der STAMPEDE Studie, Arm H
42. Long-Term Outcomes and Genetic Predictors of Response to Metastasis-Directed Therapy Versus Observation in Oligometastatic Prostate Cancer: Analysis of STOMP and ORIOLE Trials
43. External Validation of the 2003 Leibovich Prognostic Score in Patients Randomly Assigned to SORCE, an International Phase III Trial of Adjuvant Sorafenib in Renal Cell Cancer
44. Predicting prostate cancer-specific outcome after radical prostatectomy among men with very high-risk cT3b/4 PCa: a multi-institutional outcome study of 266 patients
45. Apalutamide compared with darolutamide for the treatment of non-metastatic castration resistant prostate cancer: efficacy and tolerability in a matching-adjusted indirect comparison
46. PO-1406 Hematological toxicity in pN1 prostate cancer patients treated with extended field irradiation
47. Непрямое сравнение эффективности и безопасности апалутамида и даролутамида для лечения неметастатического кастрационно-резистентного рака предстательной железы по результатам двух независимых исследований с поправкой на разницу между популяциями пациентов
48. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer
49. EAU guidelines on prostate cancer. Part I: screening, diagnosis, and treatment of clinically localised disease
50. Perioperative morbidity of surgical metastasectomy for renal cell carcinoma: An international multicenter study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.